94 related articles for article (PubMed ID: 3790708)
1. New survival curve model for comparison of adjuvant therapy of malignant diseases.
Eriguchi M; Mathé G
Biomed Pharmacother; 1986; 40(4):143-7. PubMed ID: 3790708
[TBL] [Abstract][Full Text] [Related]
2. Implications of survival curve slopes on the interpretation of adjuvant therapy results.
Eriguchi M; Mathé G
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):93-7. PubMed ID: 2743534
[TBL] [Abstract][Full Text] [Related]
3. Implications of survival curve slopes on the interpretation of adjuvant therapy results.
Eriguchi M; Mathé G
Suppl J Med Oncol Tumor Pharmacother; 1988; 1():93-7. PubMed ID: 3074230
[No Abstract] [Full Text] [Related]
4. Comparison of clinical protocols through the mathematical results analysis of survival curves.
Eriguchi M; Mathé G
Drugs Exp Clin Res; 1986; 12(1-3):51-6. PubMed ID: 3732055
[TBL] [Abstract][Full Text] [Related]
5. Scientific criticisms of the comparison of exponential survival and disease-free survival curves.
Mathé G; Eriguchi M
Biomed Pharmacother; 1988; 42(3):177-86. PubMed ID: 3179403
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
Mathé G; Reizenstein P; Eriguchi M
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):75-92. PubMed ID: 2663216
[TBL] [Abstract][Full Text] [Related]
7. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
9. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
[TBL] [Abstract][Full Text] [Related]
10. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
Smith RE; Colangelo L; Wieand HS; Begovic M; Wolmark N
J Natl Cancer Inst; 2004 Aug; 96(15):1128-32. PubMed ID: 15292384
[TBL] [Abstract][Full Text] [Related]
13. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
14. Second malignancies after a gastrectomy for gastric cancers: the effects of adjuvant therapies.
Nio Y; Hirahara N; Minari Y; Sasaki S; Takamura M; Sato Y; Inoue Y; Nagami H; Tamura K
Anticancer Res; 1999; 19(4C):3591-9. PubMed ID: 10629657
[TBL] [Abstract][Full Text] [Related]
15. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
16. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
Mayers C; Panzarella T; Tannock IF
Cancer; 2001 Jun; 91(12):2246-57. PubMed ID: 11413512
[TBL] [Abstract][Full Text] [Related]
18. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
Crivellari D; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Lindtner J; Fey MF; Senn HJ; Coates AS; Collins J; Goldhirsch A;
J Clin Oncol; 2003 Dec; 21(24):4517-23. PubMed ID: 14673038
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
